Na‐Bangchang 2004.

Methods	Randomized controlled trial Generation of allocation sequence: method not mentioned Allocation concealment: not mentioned Blinding: not mentioned Inclusion of all randomized participants: ITT or per protocol profile not included, but all 25 participants completed treatment Duration: 2000 to 2002
Participants	Number randomized: 25 Inclusion criteria: age 18 to 69 years; bodyweight 43 to 63 kg; parasitologically confirmed second‐stage T. b. gambiense infection Exclusion criteria: pregnancy; lactating women; Glasgow coma scale < 8; chronic medical condition or critically ill Diagnosis and follow‐up methods: Miniature anion exchange centrifugation technique and double centrifuge for detection of trypanosomes, cerebrospinal fluid (CSF) WBC
Interventions	1. Eflornithine, oral, 400 mg/kg/day (100 mg/kg every 6 h) for 14 days 2. Eflornithine, oral, 500 mg/kg/day (125 mg/kg every 6 h) for 14 days All participants pretreated with chloroquine and albendazole
Outcomes	1. Cure rates 2. Death 3. Adverse events Pharmacokinetics analysis
Notes	Location: Daloa, Cote d'Ivoire Setting: research centre Source of funding: UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Patients were randomly allocated but method not specified
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not mentioned in report
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data from all 25 patients were analysed